Issue Date: August 6, 2012
Mersana Raises Cash, Teams With Adimab
Mersana Therapeutics has raised $27 million in a round of financing led by New Enterprise Associates, a new investor in the biotech firm. Pfizer Venture Investments is also a new investor in the financing round, which will help Mersana develop antibody-drug conjugates (ADCs). Separately, Mersana has teamed with Adimab to offer integrated antibody discovery and ADC technology. Adimab will optimize antibodies for use with Mersana’s Fleximer polymer and linker technology.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society